Overview

Dr. Livnat Savitzky has served since 2017 as CEO and board member of FutuRx, an Israeli biotech accelerator backed by OrbiMed, Johnson & Johnson Innovation, Takeda Ventures, and recently LEAPS by Bayer, in collaboration with the Israeli Innovation Authority. .

Dr. Savitzky is a board member at Compugen (Nasdaq: CGEN) and  Ramot,.

From 2010 to 2016, she was CEO of BioLineRX, leading strategic deals with Novartis, Perrigo, MSD, and Genentech, and overseeing all aspects of company operations.

Earlier, she held senior roles at Compugen, and earned her Ph.D. in Human Genetics from Tel Aviv University, with prior degrees from Tel Aviv University and the Hebrew University of Jerusalem.